Arginine monodecanoate for biofilm disruption and candida eradication
Wintermute Biomedical has developed arginine monodecanoate, a novel antimicrobial compound effective against biofilms and Candida species. It combines L-arginine and decanoic acid to form micelles that disrupt pathogens, offering a promising solution for vaginal yeast infections.
Overview
Wintermute Biomedical has introduced arginine monodecanoate, a water-soluble ammonium carboxylate salt derived from L-arginine and decanoic acid. This compound forms antimicrobial micelles that effectively disrupt biofilms and demonstrate significant activity against pathogens such as Candida albicans and Candida auris. By leveraging the generally recognized as safe and effective (GRASE) status of its ingredients, arginine monodecanoate presents a promising, safe, and cost-effective option for treating vaginal yeast infections. Its natural foaming property and stability make it an ideal candidate for over-the-counter applications, especially when combined with antifungal agents like clotrimazole.
Technical specifications
- Composition: The compound consists of three ingredients: water, L-arginine, and decanoic acid.
- Properties: It is thermostable, inexpensive to produce, and naturally foams.
- Applications: Potential use as a foam or cream for the eradication of vaginal yeast infections, particularly effective against Candida species.
- Compatibility: Can be compounded with clotrimazole for enhanced antifungal efficacy.
Technology readiness level
Currently at TRL 5, arginine monodecanoate has demonstrated efficacy and safety in preliminary tests against various pathogens. A clinical trial is planned in Australia to evaluate the combination of arginine monodecanoate and clotrimazole in treating Candida infections. The trial aims to advance the compound to phase IB study, with completion and data delivery expected by Q4 2025.
About Wintermute Biomedical Inc.
Wintermute Biomedical is a research-led biopharmaceutical company headquartered in Melbourne, Australia, with operations in the United States. The company specializes in the development of next-generation antimicrobial therapies by utilizing a patented platform that enables the aqueous formulation of medium- and long-chain fatty acids. Their primary therapeutic candidate is Solexan, an investigational topical treatment designed to address shingles and associated pain by leveraging the antimicrobial properties of undecylenic acid. The company differentiates its approach by focusing on evidence-driven clinical research, seeking to translate academic and medical findings into effective, clinically tested treatments for infectious diseases and antimicrobial resistance.
This work addresses significant unmet clinical needs for patients suffering from conditions such as shingles, which affects approximately one million people annually in the United States. By advancing Solexan through clinical trials, including the ZOSTER EASE Phase Ib study, Wintermute Biomedical aims to provide a more targeted therapy compared to currently available standard treatments. The company collaborates with clinical partners and academic institutions to conduct rigorous, patient-centered trials that evaluate safety, tolerability, and healing efficacy. These efforts are supported by private investment, including a successful 1.3 million USD funding round, and the company continues to expand its board and strategic leadership to progress its pipeline of novel antimicrobial formulations.
delivered to your inbox.